AiCuris' letermovir meets CMV endpoints

AiCuris GmbH & Co. KG (Wuppertal, Germany) said once-daily 240 mg oral letermovir met the co-primary endpoints in a Phase II trial to prevent cytomegalovirus (CMV) infection in human blood precursor c...